Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition
John L. Allinson, FIBMS, Vice President, Biomarker Laboratory Services, ICON Development Solutions
Zoran Antonijevic, Ph.D., Senior Director, Center for Statistics in Drug Development, Innovation, Quintiles
Haifeng Bao, Ph.D., Research & Development, Translational Sciences, Medimmune
Emily Boja, Ph.D., Program Manager, Clinical Proteomic Technologies for Cancer, Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health
Brian Buxton, M.B.A., Principal, Easton Associates, LLC
Walter P. Carney, Ph.D., Head, Oncogene Science, Siemens Healthcare Diagnostics, Inc.
Jeffrey J. Chalmers, Ph.D., Professor, Department of Chemical and Biomolecular Engineering, The Ohio State University
Mark Chance, Ph.D., Professor and Director, Center for Proteomics and Bioinformatics, Case Western Reserve University
Jason Clark, Ph.D., Associate Director, BARDS, Merck Research Labs
Brent Cochran, Ph.D., Principle Investigator, Physiology, Tufts University School of Medicine
Robert Cuffe, Ph.D., Statistician, Infectious Diseases, Medicine Development Centre, GlaxoSmithKline
Viswanath Devanarayan, Ph.D., Director, Exploratory Statistics, Abbott Laboratories
Asif Dhar, M.D., M.B.A., Senior Fellow, Deloitte Center for Health Solutions; Chief Medical Informatics Officer, Deloitte Consulting LLP
Luis Diaz, Ph.D., Assistant Professor, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Krassen Dimitrov, Ph.D., Group Leader, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Australia
Jennifer Dudinak, Ph.D., Global Head, Inflammation, Regulatory Affairs, Roche
Brian T. Edmonds, Ph.D., Research Advisor, Global External Research & Development, Lilly Corporate Center
Dean W. Felsher, M.D., Ph.D., Associate Professor, Division of Oncology, Departments of Medicine and Pathology, Stanford University
Martin Fleisher, Ph.D., Chair, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center
Markus H. Frank, M.D., Assistant Professor, Department of Pediatrics, Harvard Medical School; Assistant Professor, Pediatrics, Children's Hospital Boston; Associate Physician, Medicine, Brigham and Women's Hospital
Jian-Xin Gao, M.D., Ph.D., Assistant Professor, Department of Pathology, Ohio State University Medical Center
Jeffrey N. Gibbs, J.D., Director, Hyman, Phelps and McNamara, P.C.
Erich A. Gombocz, Ph.D., Vice President & CSO, IO Informatics, Inc.
Eric D. Green, M.D., Ph.D., Director, National Human Genome Research Institute, National Institutes of Health
Andrew Grupe, Ph.D., Senior Director, Pharmacogenomics Research & Development, Celera Diagnostics
Adam Hamm, Ph.D., Director, Biostatistics, Clinsys Clinical Research
Franz Hessel, M.D., M.P.H., Director, International Health Economics Outcomes Research, Abbott Diagnostics
Renee Deehan Kenney, Ph.D., Senior Director, Scientific Research and Operations, Discovery, Genstruct, Inc.
Joshua LaBaer, M.D., Ph.D., Director, Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University
Douglas F. Lake, Ph.D., Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University
Andrea H. Lauber, Ph.D., Head, Transactions for Clinical Biomarkers and Pharmacodiagnostics, Strategic Transactions Group, Bristol-Myers Squibb Co.
Jae K. Lee, Ph.D., Director and Associate Professor, Biostatistics and Epidemiology, Department of Public Health Sciences, University of Virginia School of Medicine
Kenneth Liu, Ph.D., Senior Biometrician, Merck & Co.
Minetta C. Liu, M.D., Associate Professor, Medicine and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital
Nita Maihle, Ph.D., Professor, Ob/Gyn & Reproductive Sciences and Pathology, Yale University School of Medicine
Ramkumar Mandalam, President & CEO, Cellerant Therapeutics
David H. Manner, Ph.D., Group Leader, Exploratory and Programme Medical Statistics, Eli Lilly
Ruth E. March, Ph.D., Personalized Healthcare Leader, AstraZeneca
Robert McCormack, Ph.D., Vice President, Scientific and Medical Affairs, Veridex, LLC
Gerry J. McDougall, Partner, Personalized Medicine and Health Sciences Practices, PricewaterhouseCoopers LLP
Gary Means, Ph.D., Principal Scientist, Molecular Sciences Group, Amgen, Inc.
Iain D. Miller, Ph.D., Executive Director, Theranostics Strategy and Business Development, bioMerieux
David Nelson, Ph.D., President and CEO, Epic Sciences, Inc.
Raymond T. Ng, Ph.D., CIO, PROOF Centre of Excellence; Professor, Computer Science, University of British Columbia
Gilbert S. Omenn, M.D., Ph.D., Director, Center for Computational Medicine and Bioinformatics, University of Michigan School of Medicine
Jun Lu, Ph.D., Assistant Professor, Yale University Department of Genetics, Yale Stem Cell Center
Itay Perlstein, Ph.D., Scientist, Quantitative Clinical Pharmacology, Merck & Co., Inc.
Emanuel Petricoin, Ph.D., Co-Director, Center for Applied Proteomics and Molecular Medicine; Professor, Life Sciences, George Mason University
Elizabeth Punnoose, Ph.D., Scientist, Development Oncology Diagnostics, Genentech, Inc.
Bharat Rao, Ph.D., Head, Knowledge Solutions Group, Image and Knowledge Management (IKM CKS) Division, Siemens Healthcare
Thomas Ried, M.D., Chief, Section of Cancer Genomics, National Cancer Institute, National Institutes of Health
Donna Roscoe, Ph.D., Scientific Reviewer, DIHD/OIVD/CDRH, U.S. Food and Drug Administration
Allan Rosen, M.S., Associate Director, Biostatistics, Kendle International, Inc.
Mollie Roth, J.D., Corporate Counsel, Vice President, Business Development, Diaceutics; Visiting Faculty Fellow, Center for Law, Science and Innovation, The Sandra Day O'Connor College of Law, Arizona State University
David R. Shalinsky, Ph.D., Associate Director, Translational Oncology, Pfizer Oncology Business Unit, Pfizer, Inc.
Zhenming Shun, Ph.D., Director, U.S. Head, Oncology, Biostatistics and Programming, Sanofi-Aventis
Yu Shyr, Ph.D., Professor and Chief, Division of Cancer Biostatistics, Department of Biostatistics; Director, Cancer Biostatistics Center, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research, Vanderbilt University School of Medicine
Ashwani Sood, Ph.D., Member and Assistant Professor, Oncology, Department of Microbiology and Immunology, SUNY at Buffalo, Roswell Park Cancer Institute
Daniel S. Spellman, Ph.D., Senior Research Biochemist, Proteomics, Merck Research Laboratories
Zoltan Szallasi, M.D., Senior Scientist, Informatics Program, Children's Hospital Boston, Harvard Medical School
Kay S. Tatsuoka, Ph.D., Manager, Discovery Biometrics & Quantitative Sciences, GlaxoSmithKline
Paul Tempst, Ph.D., Director, Protein Center; Member and Professor, Molecular Biology Program, Memorial Sloan-Kettering Cancer Center
Živana Težak, Ph.D., Associate Director for Science and Technology, Personalized Medicine/OIVD/CDRH, U.S. Food and Drug Administration
Kirsten Vang Nielsen, Ph.D., Senior Principal Scientist, Research & Development, Dako A/S
Pantelis Vlachos, Ph.D., Principal Biostatistician, Merck Serono International S.A.
J. Kyle Wathen, Ph.D., Research Statistician, University of Texas, M.D. Anderson Cancer Center
Glen Weiss, M.D., Co-Head, Lung Cancer Unit, Translational Genomics Research Institute (TGen); Director, Thoracic Oncology, TGen Clinical Research Services at Scottsdale Healthcare
Anne Wiles, Advanced Analytics Strategist, Health and Life Sciences, SAS Institute, Inc.
Stephen Wong, Ph.D., Director, Center for Bioengineering and Informatics, The Methodist Hospital Research Institute, Weill Cornell Medical College
Vladimir Zharov, Ph.D., Professor and Director, Philips Classic Laser & Nanomedicine Laboratories; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences